Rohan Ramakrishna, M.D.

You are here

Rohan Ramakrishna, M.D.

Dr. Rohan Ramakrishna is an award-winning neurosurgeon who specializes in the treatment of brain tumors and other central nervous system tumors. Dr. Ramakrishna treats patients with gliomas, metastatic disease, skull base lesions, and pituitary disorders. He employs advanced awake mapping, imaging techniques, and microsurgery to ensure maximal tumor removal and achieve the safest possible surgical outcomes. Dr. Ramakrishna has advanced training in some of the most leading-edge technologies available, allowing him to  provide the latest, most efficient options for each patient. These technologies include advanced  laser surgery, minimally invasive subcortical and  interventricular surgery, brain mapping, and advanced open/endoscopic skull base techniques. Furthermore, Dr. Ramakrishna works with a multi-disciplinary team to ensure that the best possible treatment strategies are offered to his patients. He sees patients at the Brain Tumor Center at New York Presbyterian/Weill Cornell Medical Center as part of the surgical neuro-oncology team.

One of Dr. Ramakrishna's patients was recently featured in a NewYork-Presbyterian "Amazing Things" ad:

Training
Dr. Ramakrishna received his Bachelor of Arts from the University of Pennsylvania, majoring in Biology and Philosophy, and was elected to the Phi Beta Kappa society upon graduation. He obtained his medical degree from the University of Pennsylvania. Dr. Ramakrishna completed his neurosurgery residency and served as chief resident at the University of Washington. He then went on to complete a fellowship in neurosurgical oncology at the MD Anderson Cancer Center in Houston, Texas.

Research
Dr. Ramakrishna’s research interests include novel drug delivery strategies to treat malignant brain and skull base tumors using advanced polymer and nanoparticle technology. Additionally, Dr. Ramakrishna is interested in developing new vaccine-based therapies for glioma and in helping to develop new clinical trials and outcome measures to advance the care of brain tumors. He has published and spoken extensively on these topics and has received multiple awards, including prestigious training and research grants from the NIH and the Fred Hutchinson Cancer Consortium.

 

See more about Dr. Ramakrishna's new clinical trial using Toca-511 for glioblastoma multiforme (GBM)     
   

Request an Appointment